Usually disagree with your outlook but I think your mostly on the money here. The only nuance to that is with the small pop in the share price we move to a somewhat higher trading range and leave the teens for good. But in a catch 22 kind of way, I find this assessment optimistic because I am more often than not wrong with my assessments. When the tutes think your beaten down is when the SP will rise to the next level. What would do that? I think perhaps BTD(s) and any evidence that SPPI is able to execute on their plan and don't let timelines slip as they did by a year for Rolontis (so far). As I mentioned in a previous post, if Spectrum is executing on recruiting for their pozi trial and the EGFR cohort has stopped recruiting that would be a significant event since in all likelihood the clock starts ticking on approval and significant revenue within a year. Also, now that more solid pozi data is in hand, I expect real negotiations are picking up on licencing deals w pozi for the EU and Japan and perhaps a co-licencing deal in the US since Spectrum will have a better hand to play in negotiations.
So to summarize, I think the share price may settle in a slightly higher trading range ($22 to $27?) but there are events that can increase that slightly to significantly in the not too distant future. We'll see. Here's to confirming promising data tomorrow afternoon!
